DOCSLIB.ORG

Official Title: a MULTICENTER, OPEN-LABEL, PHASE III CLINICAL

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Official Title: a MULTICENTER, OPEN-LABEL, PHASE III CLINICAL Official Title: A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS NCT Number: NCT02795767 Document: PROTOCOL Version & Date: Version 4: 01 September 2017 PROTOCOL TITLE: A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS PROTOCOL NUMBER: BH29992 VERSION NUMBER: 4 EUDRACT NUMBER: 2016-000073-21 IND NUMBER: 122954 TEST PRODUCT: Emicizumab (RO5534262) MEDICAL MONITOR: M.D., M.A.S. SPONSOR: F. Hoffmann-La Roche Ltd and Chugai Pharmaceutical Co. Ltd. DATE FINAL: 20 January 2016 DATES AMENDMED: Version 2: 12 July 2016 Version 3: 8 December 2016 Version 4: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 01-Sep-2017 18:27:12 CONFIDENTIAL F. Hoffmann-La Roche Ltd of Basel, Switzerland, and Chugai Pharmaceutical Co. Ltd.* of Tokyo, Japan, will act as co-sponsors of this global study. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States, or Chugai Pharmaceutical Co. Ltd.* in South Korea, Taiwan, and Japan. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. *Chugai will act as the Sponsor only in South Korea, Taiwan, and Japan. The specific details of the legal/regulatory entity within the relevant country are provided within the clinical trial agreement with the Investigator/Institution and the Clinical Trial Application with the Competent Authority. Emicizumab—F. Hoffmann-La Roche Ltd Protocol BH29992, Version 4 PROTOCOL AMENDMENT, VERSION 4: RATIONALE Protocol BH29992 has been primarily amended to evaluate additional emicizumab dosing schedules and to update safety information. Changes to the protocol, along with a rationale for each change, are summarized below: Two cohorts (designated as Cohorts B and C; patients 211 years of age) have been added to the study to investigate additional less frequent emicizumab dosing schedules (every 2 weeks [Q2W] and every 4 weeks [Q4W]), which would allow the option to select a preferred schedule, while still delivering the same cumulative dose (Sections 1.3, 3.3.1, 3.3.1.1, and 6.9.1.1). The addition of these cohorts is reflected throughout the protocol (Sections 16). Recent safety findings of thrombotic microangiopathy (TMA) observed in Study BH29884 have been added (Sections 1.2, 3.1, and 5.1.1.4). Clarification regarding laboratory monitoring of coagulation status after any bypassing agent use has been added. Laboratory monitoring is to be done after any use of a bypassing agent, and not only after use of a bypassing agent to treat breakthrough bleeds (Section 5.1.2). An exclusion criterion has been added for patients who are unable to or unwilling to receive blood or blood products (or any standard-of-care treatment for a life-threatening condition). This criterion has been added in context of a fatal outcome from a life-threatening rectal hemorrhage in Study BH29884 in a patient who declined receipt of blood and blood products (Sections 4.3 and 5.1.1.4). The up-titration schema has been modified with removal of the 2.25-mg/kg once weekly (QW) dosing level. This is based on an interim data review characterizing exposure at 1.5 mg/kg QW in patients 212 years of age to be similar to adolescent/adult patients (Section 4.5.2). As such, the up-titration dose will be the same used in adolescent/adult patients (3 mg/kg QW). A new safety risk associated with emicizumab has been added as follows: Life-threatening bleeding due to unreliable standard coagulation tests and inhibitors assays in the setting of emicizumab Coagulation laboratory tests (including, but not limited to, aPTT, one-stage FVIII activity, and FVIII inhibitor measurement by Bethesda assay) are not reliable and are impacted by the presence of emicizumab and, therefore, are not reflecting the patient’s underlying hemostatic status accurately (Section 5.1.1.5). The reporting of the term “sudden death” has been updated to also require the presumed cause of death (Section 5.3.5.8). Event reporting for hospitalization has been clarified (Section 5.3.5.11). The process for reviewing and handling protocol deviations has been updated per internal standard operating procedures (Section 9.2). Emicizumab—F. Hoffmann-La Roche Ltd 2/Protocol BH29992, Version 4 Additional minor changes have been made to improve clarity, consistency, and alignment with the other emicizumab protocols. Substantive new information appears in italics. This amendment represents cumulative changes to the original protocol. Emicizumab—F. Hoffmann-La Roche Ltd 3/Protocol BH29992, Version 4 PROTOCOL AMENDMENT, VERSION 4: SUMMARY OF CHANGES PROTOCOL TITLE The protocol title has been revised as follows: A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS PROTOCOL SYNOPSIS The protocol synopsis has been updated to reflect the changes to the protocol, where applicable. SECTION 1.2: BACKGROUND ON EMICIZUMAB Clinical Studies … Two severe adverse events were observed: appendicitis and mesenteric hematoma. Both events were considered to be serious adverse events and not related to emicizumab administration. In the Phase I/II Studies ACE001JP and ACE002JP, no thrombotic microangiopathy (TMA), thromboembolic adverse events, or systemic hypersensitivity reactions have been reported in any dosing cohort thus far, including those patients who required concomitant FVIII concentrates or bypassing agent therapy to treat bleeds. In the ongoing Phase III Study BH29884 (adolescent and adult patients with hemophilia A with FVIII inhibitors), as of November April 20176, TMA thrombotic microangiopathy (TMA; atypical hemolytic uremic syndrome [aHUS]) was observed in 32 patients receiving emicizumab and bypassing agents; and 32 cases of serious thromboembolic events were observed in 2 patients receiving emicizumab and bypassing agents. For more details refer to Sections 5.1.1.3 and 5.1.1.4. SECTION 1.3: STUDY RATIONALE AND BENEFIT–RISK ASSESSMENT … In these studies, no thromboembolic or systemic hypersensitivity adverse events were observed; however, in the ongoing Phase III Study BH29884,32 cases of TMA (aHUS) and 2 3 serious thromboembolic events were observed in patients on emicizumab who received bypassing agents for the treatment of breakthrough bleeds. Three Four out of these 54 patients have fully recovered and the fourth patient’s condition has improved, and 1 patient died due to severe rectal bleeding (see Sections 5.1.1.3 and 5.1.1.4). This current study is designed to evaluate the efficacy, safety, and pharmacokinetics of emicizumab administered subcutaneously initially once weekly (QW) in pediatric patients with hemophilia A with FVIII inhibitors. Following review of data in adult and adolescent patients with hemophilia A from two ongoing Phase III studies Emicizumab—F. Hoffmann-La Roche Ltd 4/Protocol BH29992, Version 4 evaluating emicizumab at 3 mg/kg every 2 weeks (Q2W; BH30071) and 6 mg/kg every 4 weeks (Q4W; BO39182), this study will open two additional non-randomized cohorts to investigate Q2W and Q4W regimens in pediatric patients (see Section 3.3.1). SECTION 2: OBJECTIVES AND ENDPOINTS The objectives of the study are to investigate (with no formal hypothesis testing) the efficacy, safety, and pharmacokinetics of once weekly SC administration of emicizumab administered at 1.5 mg/kg QW, 3 mg/kg Q2W, and 6 mg/kg Q4W in pediatric patients with hemophilia A and FVIII inhibitors who are currently receiving treatment with bypassing agents. A total of approximately 80 patients are planned: approximately 60 patients in Cohort A (1.5 mg/kg QW) and approximately 10 patients each in Cohort B (3 mg/kg Q2W) and Cohort C (6 mg/kg Q4W). At least 20 pPatients younger than 12 years old of age and up to 60 patients are planned for enrollment, with allowance of patients 1217 years of age who weigh 40 kg at the time of informed consent to further evaluate dosing of emicizumab in patients 40 kg. Of note, enrollment in Cohort A may be left open exclusively for patients 2 years of age until approximately 5 such patients have been enrolled. SECTION 2.1: EFFICACY OBJECTIVES The endpoints will be analyzed separately for the three cohorts: Cohort A (1.5 mg/kg QW), Cohort B (3 mg/kg Q2W), and Cohort C (6 mg/kg Q4W), and overall as appropriate. The efficacy objectives for this study are as follows: To evaluate the clinical effect of prophylactic emicizumab on the number of bleeds over time (i.e., bleed rate) * To evaluate the efficacy in reducing the number of bleeds over time compared with the patient's historical bleed rate (intra-patient comparison, Cohort A
Load more

Recommended publications
  • PAGE Program 2019
    PAGE Program 2019 Tuesday 11 June 14:00-18:00 Registration at the Conference Venue 18:00-19:30 Welcome reception with drinks and light snacks (no dinner) Wednesday 12 June 08:00-08:45 Registration 08:45-09:00 Welcome and Introduction 09:00-09:45 Keynote lecture Chair: Dinesh De Alwis Pharmacometrics: A shot in the arm for vaccine discovery and 09:00-09:45 Jeff Sachs development ~or~ Vaccines are not immune to the charms of pharmacometrics 09:45-09:50 PAGE scientific program Siv Jönsson 09:50-11:15 Coffee break, Poster and Software session I Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 11:15-12:15 Infectious diseases Chair: France Mentré Stratified medicine approaches for drug susceptible tuberculosis 11:15-11:35 Marjorie Imperial patients Repeated time-to-event models support that Pseudomonas 11:35-11:55 Stefanie Hennig aeruginosa infection increase the risk of acquiring Aspergillus in young children with cystic fibrosis María García- Individual level data meta-analysis from HIV pre-exposure 11:55-12:15 Cremades prophylaxis (PrEP) clinical trials 12:15-13:45 Lunch 13:45-14:30 Tutorial Chair: Mats Karlsson 13:45-14:30 Nicky Best Use of informative priors in model-informed drug development Page | 1 Chairs: Mats Karlsson, 14:30-15:10 Machine learning in oncology Paolo Magni Machine learning combined to mechanistic modeling of 14:30-14:50 Chiara Nicolò differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth Machine learning versus mechanistic modeling for prediction
    [Show full text]
  • Supplementum 237 (June 21, 2019)
    SMW Established in 1871 Swiss Medical Weekly Formerly: Schweizerische Medizinische Wochenschrift An open access, online journal • www.smw.ch Supplementum 237 Swiss Oncology & Hematology Congress (SOHC) ad Swiss Med Wkly Zurich (Switzerland), June 26–28, 2019 2019;149 June 21, 2019 Abstracts SWISS HEMATOLOGY & ONCOLOGY CONGRESS (SOHC) ZURICH (SWITZERLAND), JUNE 26‒28, 2019 WWW.SOHC.CH TABLE OF CONTENTS 2 S Clinical hemato-oncology (lymphoma, myeloma, leukemia, transplantation for SSH and SSMO) 11 S Clinical solid tumor oncology 18 S Experimental hematology / oncology 27 S Hemostasis, transfusion medicine, vascular, laboratory medicine 40 S Index of first authors SAVE THE DATE: SWISS HEMATOLOGY & ONCOLOGY CONGRESS (SOHC) NOVEMBER 19‒21, 2020 RADISSON BLU HOTEL, ZURICH AIRPORT Swiss Medical Weekly 2019;149 (Suppl. 237) ● www.smw.ch EMHMedia SWISS ONCOLOGY & HEMATOLOGY CONGRESS, JUNE 26‒28, 2019 2 S CLINICAL HEMATO-ONCOLOGY (LYMPHOMA, MYELOMA, LEUKEMIA, TRANSPLANTATION FOR SSH AND SSMO) 993 1002 In children with chemotherapy 39.0°C is a safe fever limit. The ran- Time to antibiotics and clinical outcomes in fever and neutropenia domized controlled multicenter SPOG 2015 FN Definition Study during chemotherapy for cancer, a systematic review Koenig C1, Bodmer N2, Agyeman P3, Niggli F2, Adam C4, Ansari M5,6, Koenig C1, Schneider C1, Morgan J2, Ammann RA3, Sung L4, Phillips B2 Eisenreich B7, Keller N1, Leibundgut K1, Nadal D2, Roessler J1, 1Bern University Hospital, University of Bern, Bern; 2Centre for Reviews and Dis- Scheinemann K8,9,10, Simon
    [Show full text]
  • Blood Reviews 35 (2019) 43–50
    Blood Reviews 35 (2019) 43–50 Contents lists available at ScienceDirect Blood Reviews journal homepage: www.elsevier.com/locate/blre Review Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis T ⁎ Bethany Samuelson Bannowa, , Michael Rechta, Claude Négrierb, Cédric Hermansc, Erik Berntorpd, Hermann Eichlere, Maria Elisa Mancusof, Robert Klamrothg, Jamie O'Harah, Elena Santagostinoi, Tadashi Matsushitai, Craig Kesslerj a The Hemophilia Center at Oregon Health & Science University, 707 SW Gaines Ave, Portland, OR 97239, United States b Hospital Louis Pradel, University Claude Bernard Lyon 1, 59 Boulevard Pinel, 69677 Bron Cedex, France c Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 1200 Brussels, Belgium d Malmö Centre for Thrombosis and Haemostasis, Lund University, Skane University Hospital, Jan Waldenströms gata 14, SE-214 28, Malmö, Sweden e Saarland University Hospital, Haemophila Centre, Institute for Clinical Haemostaseology and Transfusion Medicine, 66421 Homburg, Germany f Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy g Vivantes Klinikum im Friedrichshain, Center for Hemophilia and Hemostaseology, Landsberger Allee 49, 10249 Berlin, Germany h HCD Economics, The Innovation Centre, Keckwick Lane, Daresbury, Cheshire WA4 4FS, UK i Department of Transfusion Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan j Georgetown University Medical Center, Washington, DC, USA ARTICLE INFO ABSTRACT Keywords: Factor VIII protein (FVIII) as a coagulation replacement factor has for decades been used as the standard of care Haemophilia for management of people with haemophilia A. It is effective for treatment of bleeding events, as prophylaxis to FVIII prevent bleeding events and preserve joint function, and to support surgery in people with haemophilia A.
    [Show full text]
  • Valoctocogene Roxaparvovec and Emicizumab for Hemophilia a Without Inhibitors: Effectiveness and Value
    Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value Final Report Prepared for ©Institute for Clinical and Economic Review, 2020 University of Illinois at Chicago College of Pharmacy ICER Staff Modeling Group David M. Rind, MD, MSc Surrey M. Walton, PhD Chief Medical Officer Professor, Pharmacy Systems, Outcomes and Policy ICER Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research University of Illinois at Foluso Agboola, MBBS, MPH Chicago College of Pharmacy Director, Evidence Synthesis ICER Danny Quach, PharmD University of Illinois at Chicago College of Pharmacy Serina Herron-Smith, BS Research Assistant ICER Rick Chapman, PhD, MS Director of Health Economics ICER Steven D. Pearson, MD, MSc President ICER Pamela Bradt, MD, MPH Chief Scientific Officer ICER The role of the University of Illinois (UIC) College of Pharmacy Modeling Group is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UIC. DATE OF PUBLICATION: November 20, 2020 How to cite this document: Rind DM, Walton SM, Agboola F, Herron-Smith S, Quach D, Chapman R, Pearson SD, Bradt P. Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A: Effectiveness and Value; Final Report. Institute for Clinical and Economic Review, November 20, 2020. https://icer- review.org/material/hemophilia-a-update-final-evidence-report/ David Rind served as the lead author for the report and wrote the background, other benefits, and contextual considerations sections of the report. Foluso Agboola was responsible for the oversight of the systematic review and authorship of the comparative clinical effectiveness section with the support of Serina Herron-Smith and Eric Borrelli.
    [Show full text]
  • Emicizumab for Hemophilia a with Inhibitors: Effectiveness and Value
    Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value Evidence Report March 15, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 University of Washington School of Pharmacy ICER Staff Modeling Group David Rind, MD Lotte Steuten, MSc, PhD Chief Medical Officer University of Washington Institute for Clinical and Economic Review Gregory Guzauskas, MSPH, PhD Foluso Agboola, MBBS, MPH University of Washington Research Scientist Institute for Clinical and Economic Review Varun Kumar, MBBS, MPH, MSc Health Economist Institute for Clinical and Economic Review Celia Segel, MPP Program Manager Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical and Economic Review Alexandra Ellis, MSc, AM Senior Scientist, HTA and Economic Evaluation Institute for Clinical and Economic Review Daniel A. Ollendorf, PhD Chief Scientific Officer Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review DATE OF PUBLICATION: March 15, 2018 David Rind served as the lead author for the report. Foluso Agboola led the systematic review and authorship of the comparative clinical effectiveness section. Varun Kumar and Rick Chapman were responsible for oversight of the cost-effectiveness analyses and developed the budget impact model. Celia Segel authored the section on coverage policies and clinical guidelines. Alexandra Ellis, Dan Ollendorf, and Steven Pearson provided methodologic guidance on the clinical and economic evaluations. The role of the University of Washington (UW) School of Pharmacy Modeling Group is limited to the development of the cost-effectiveness model, and the resulting ICER reports do not necessarily represent the views of the UW.
    [Show full text]
  • In Hemophilia a with Or Without Factor Viii Inhibitors
    HEMLIBRA® (emicizumab-kxwh) IN HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS Media Inquiries: (650) 467-6800 About Hemlibra Hemlibra® (emicizumab-kxwh) is approved by the FDA as a prophylactic (preventative) treatment to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.1 It is administered subcutaneously (under the skin) and only once weekly, every two weeks or every four weeks. In pivotal trials, Hemlibra significantly reduced treated bleeds compared to no prophylaxis (HAVEN 1, HAVEN 2, HAVEN 3) and demonstrated clinically meaningful bleed control (HAVEN 4). • FIRST AND ONLY medicine to significantly reduce treated • The ecacy and safety of Hemlibra has been demonstrated bleeds in prospective intra-patient analyses: in one of the LARGEST PIVOTAL CLINICAL TRIAL PROGRAMS - Compared to prior treatment with factor VIII prophylaxis in in hemophilia A people with hemophilia A without factor VIII inhibitors • FIRST new class of medicine to treat hemophilia A in nearly - Compared to prior treatment with bypassing agent (BPA) 20 years prophylaxis in people with hemophilia A with factor VIII inhibitors • Bispecific monoclonal antibody that bridges factors IXa and X • ONLY approved medicine for hemophilia A that can be to help restore the blood clotting cascade self-administered subcutaneously at multiple dosing options Select Important Safety Information Hemlibra increases the potential for blood to clot. Patients should carefully follow their healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment.
    [Show full text]
  • HEMLIBRA (Emicizumab-Kxwh)
    HIGHLIGHTS OF PRESCRIBING INFORMATION 3 mg/kg once every two weeks, or These highlights do not include all the information needed to use 6 mg/kg once every four weeks. (2.1) HEMLIBRA safely and effectively. See full prescribing information for See Full Prescribing Information for important preparation and administration HEMLIBRA. instructions. (2.2) HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use Initial U.S. Approval: 2017 DOSAGE FORMS AND STRENGTHS Injection: WARNING: THROMBOTIC MICROANGIOPATHY and 30 mg/mL in a single-dose vial (3) THROMBOEMBOLISM 60 mg/0.4 mL in a single-dose vial (3) See full prescribing information for complete boxed warning. 105 mg/0.7 mL in a single-dose vial (3) 150 mg/mL in a single-dose vial (3) Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of CONTRAINDICATIONS >100 U/kg/24 hours of activated prothrombin complex concentrate None (4) (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of WARNINGS AND PRECAUTIONS thrombotic microangiopathy and thrombotic events if aPCC is Laboratory Coagulation Test Interference: HEMLIBRA interferes with administered. Discontinue aPCC and suspend dosing of HEMLIBRA activated clotting time (ACT), activated partial thromboplastin time if symptoms occur. (aPTT), and coagulation laboratory tests based on aPTT, including one- stage aPTT-based single-factor assays, aPTT-based Activated Protein C RECENT MAJOR CHANGES Resistance (APC-R), and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based Indications and Usage (1) 10/2018 Dosage and Administration (2.1) 10/2018 laboratory tests should not be used.
    [Show full text]
  • Assessment Report
    25 January 2018 EMA/88475/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hemlibra International non-proprietary name: emicizumab Procedure No. EMEA/H/C/004406/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents Background information on the procedure .................................................. 8 1.1. Submission of the dossier ..................................................................................... 8 1.2. Steps taken for the assessment of the product ........................................................ 9 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ........................................................................................ 10 2.1.2. Epidemiology .................................................................................................. 10 2.1.3. Clinical presentation, diagnosis and prognosis ..................................................... 11 2.1.4. Management
    [Show full text]
  • Hemlibra, INN: Emicizumab
    31 January 2019 EMA/125963/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Hemlibra International non-proprietary name: emicizumab Procedure No. EMEA/H/C/004406/II/0002 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Type II variation .................................................................................................. 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Non-clinical aspects .............................................................................................. 9 2.2.1. Introduction ...................................................................................................... 9 2.2.2. Pharmacology ................................................................................................
    [Show full text]
  • Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION • 1.5 mg/kg once every week, or These highlights do not include all the information needed to use • 3 mg/kg once every two weeks, or HEMLIBRA safely and effectively. See full prescribing information for • 6 mg/kg once every four weeks. (2.1) HEMLIBRA. See Full Prescribing Information for important preparation and administration HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use instructions. (2.2) Initial U.S. Approval: 2017 DOSAGE FORMS AND STRENGTHS WARNING: THROMBOTIC MICROANGIOPATHY and Injection: THROMBOEMBOLISM • 30 mg/mL in a single-dose vial (3) See full prescribing information for complete boxed warning. • 60 mg/0.4 mL in a single-dose vial (3) • 105 mg/0.7 mL in a single-dose vial (3) Cases of thrombotic microangiopathy and thrombotic events were • 150 mg/mL in a single-dose vial (3) reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate CONTRAINDICATIONS (aPCC) was administered for 24 hours or more to patients receiving None (4) HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is WARNINGS AND PRECAUTIONS administered. Discontinue aPCC and suspend dosing of HEMLIBRA Laboratory Coagulation Test Interference: HEMLIBRA interferes with if symptoms occur. activated clotting time (ACT), activated partial thromboplastin time (aPTT), and coagulation laboratory tests based on aPTT, including one-stage aPTT- RECENT MAJOR CHANGES based single-factor assays, aPTT-based Activated Protein C Resistance (APC- Dosage and Administration R), and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor Preparation and Administration (2.2) 06/2020 titers.
    [Show full text]
  • Iron Overload in Thalassemias
    FACULTY • Sabri Kemahlı (Yeditepe University Faculty of Medicine, Istanbul, Turkey) • Güner Hayri Özsan (Dokuz Eylül University Faculty of Medicine, İzmir, Turkey) • Emin Kansu (Turkey) Hacettepe University Cancer Institute and Department of Stem Cell Sciences, Ankara – Turkey (Retired) • Chaim Hershko (Department of Medicine, Shaare Zedek Medical Center and Hebrew University Hadassah Medical School, Jerusalem, Israel) • Yeşim Aydınok (Ege University, İzmir, Turkey) • Şule Ünal (Hacettepe University, İhsan Doğramacı Child Hospital, Ankara, Turkey) • Amal El-Beshlawy (Cairo University, Egypt) • Miguel Abboud M.D. (Children’s Cancer Center of Lebanon, Beirut, Lebanon) • Elif Gülsüm Ümit (Edirne Sultan 1. Murat State Hospital, Edirne Turkey) • Kaan Kavaklı (Ege University Faculty of Medicine, İzmir, Turkey) • Ayşegül Ünüvar (Istanbul University Faculty of Medicine, İstanbul, Turkey) • Gül Nihal Özdemir (Istanbul Kanuni Sultan Süleyman Training & Research Hospital, Istanbul Turkey) • Muhlis Cem Ar (Istanbul University Faculty of Medicine, İstanbul, Turkey) • Reyhan Diz Küçükkaya (Retired, Istanbul, Turkey) • Yahya Büyükaşık (Hacettepe University Faculty of Medicine, Ankara, Turkey) • Elif Ünal İnce (AnkaraUniversity Faculty of Medicine, Ankara, Turkey) • Ayşegül Üner (Hacettepe University Faculty of Medicine, Ankara, Turkey) • Duygu Uçkan (Hacettepe University, İhsan Doğramacı Child Hospital, Ankara, Turkey) • Sema Anak (Istanbul University Faculty of Medicine, İstanbul, Turkey) 2 TABLE of CONTENTS Current Perspectives on Hematopoiesis and
    [Show full text]
  • Official Title
    Official Title: A SINGLE-CENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF EMICIZUMAB IN HEALTHY CHINESE VOLUNTEERS NCT Number: NCT03380780 Document: PROTOCOL Version & Date: Version 4: 25-Jan-2018 PROTOCOL TITLE: A SINGLE-CENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF EMICIZUMAB IN HEALTHY CHINESE VOLUNTEERS PROTOCOL NUMBER: YP39308 VERSION: 4 TEST PRODUCT: Emicizumab (RO5534262) MEDICAL MONITOR: , M.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: Version 1: 31 May 2016 DATE AMENDED: Version 2: 19 March 2017 Version 3: 10 October 2017 Version 4: See electronic date stamp below. FINAL PROTOCOL APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 25-Jan-2018 18:07:18 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Roche except to the extent necessary to obtain informed consent from persons to whom the drug may be administered. Emicizumab—F. Hoffmann-La Roche Ltd Protocol YP39308, Version 4 PROTOCOL AMENDMENT, VERSION 4: RATIONALE Protocol YP39308 has been primarily amended to update the exclusion criteria and study assessments.
    [Show full text]